These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 34733624)

  • 21. In vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAF
    Nokin MJ; Darbo E; Richard E; San José S; de Hita S; Prouzet-Mauleon V; Turcq B; Gerardelli L; Crake R; Velasco V; Koopmansch B; Lambert F; Xue JY; Sang B; Horne J; Ziemons E; Villanueva A; Blomme A; Herfs M; Cataldo D; Calvayrac O; Porporato P; Nadal E; Lito P; Jänne PA; Ricciuti B; Awad MM; Ambrogio C; Santamaría D;
    Cell Rep Med; 2024 Aug; 5(8):101663. PubMed ID: 39094577
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cyclic tachyplesin I kills proliferative, non-proliferative and drug-resistant melanoma cells without inducing resistance.
    Benfield AH; Vernen F; Young RSE; Nadal-Bufí F; Lamb H; Hammerlindl H; Craik DJ; Schaider H; Lawrence N; Blanksby SJ; Henriques ST
    Pharmacol Res; 2024 Sep; 207():107298. PubMed ID: 39032840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro validation study of HER2 and HER4 mutations identified in an ad hoc secondary analysis of the LUX-Lung 8 randomized clinical trial.
    Hamada A; Suda K; Koga T; Fujino T; Nishino M; Ohara S; Chiba M; Shimoji M; Takemoto T; Soh J; Uchida T; Mitsudomi T
    Lung Cancer; 2021 Dec; 162():79-85. PubMed ID: 34741886
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study.
    Zhou Q; Wu L; Hu P; An T; Zhou J; Zhang L; Liu XQ; Luo F; Zheng X; Cheng Y; Yang N; Li J; Feng J; Han B; Song Y; Wang K; Zhang L; Fang J; Zhao H; Shu Y; Lin XY; Chen Z; Gan B; Xu WH; Tang W; Zhang X; Yang JJ; Xu X; Wu YL
    Clin Cancer Res; 2022 Mar; 28(6):1127-1135. PubMed ID: 34740925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diverse alterations associated with resistance to KRAS(G12C) inhibition.
    Zhao Y; Murciano-Goroff YR; Xue JY; Ang A; Lucas J; Mai TT; Da Cruz Paula AF; Saiki AY; Mohn D; Achanta P; Sisk AE; Arora KS; Roy RS; Kim D; Li C; Lim LP; Li M; Bahr A; Loomis BR; de Stanchina E; Reis-Filho JS; Weigelt B; Berger M; Riely G; Arbour KC; Lipford JR; Li BT; Lito P
    Nature; 2021 Nov; 599(7886):679-683. PubMed ID: 34759319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.
    Liu SY; Bao H; Wang Q; Mao WM; Chen Y; Tong X; Xu ST; Wu L; Wei YC; Liu YY; Chen C; Cheng Y; Yin R; Yang F; Ren SX; Li XF; Li J; Huang C; Liu ZD; Xu S; Chen KN; Xu SD; Liu LX; Yu P; Wang BH; Ma HT; Yan HH; Dong S; Zhang XC; Su J; Yang JJ; Yang XN; Zhou Q; Wu X; Shao Y; Zhong WZ; Wu YL
    Nat Commun; 2021 Nov; 12(1):6450. PubMed ID: 34750392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. STEAP3 promotes cancer cell proliferation by facilitating nuclear trafficking of EGFR to enhance RAC1-ERK-STAT3 signaling in hepatocellular carcinoma.
    Wang LL; Luo J; He ZH; Liu YQ; Li HG; Xie D; Cai MY
    Cell Death Dis; 2021 Nov; 12(11):1052. PubMed ID: 34741044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. USP5 facilitates non-small cell lung cancer progression through stabilization of PD-L1.
    Pan J; Qiao Y; Chen C; Zang H; Zhang X; Qi F; Chang C; Yang F; Sun M; Lin S; Tang Q; Li L; Wang M; Wu M; Liu Y; Lai C; Chen J; Chen G
    Cell Death Dis; 2021 Nov; 12(11):1051. PubMed ID: 34741014
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diminished Efficacy of Programmed Death-(Ligand)1 Inhibition in STK11- and KEAP1-Mutant Lung Adenocarcinoma Is Affected by KRAS Mutation Status.
    Ricciuti B; Arbour KC; Lin JJ; Vajdi A; Vokes N; Hong L; Zhang J; Tolstorukov MY; Li YY; Spurr LF; Cherniack AD; Recondo G; Lamberti G; Wang X; Venkatraman D; Alessi JV; Vaz VR; Rizvi H; Egger J; Plodkowski AJ; Khosrowjerdi S; Digumarthy S; Park H; Vaz N; Nishino M; Sholl LM; Barbie D; Altan M; Heymach JV; Skoulidis F; Gainor JF; Hellmann MD; Awad MM
    J Thorac Oncol; 2022 Mar; 17(3):399-410. PubMed ID: 34740862
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Real-World Outcomes of Everolimus and Exemestane for the Treatment of Metastatic Hormone Receptor-Positive Breast Cancer in Patients Previously Treated With CDK4/6 Inhibitors.
    Mo H; Renna CE; Moore HCF; Abraham J; Kruse ML; Montero AJ; LeGrand SB; Wang L; Budd GT
    Clin Breast Cancer; 2022 Feb; 22(2):143-148. PubMed ID: 34740541
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.
    Saw SPL; Zhou S; Chen J; Lai G; Ang MK; Chua K; Kanesvaran R; Ng QS; Jain A; Tan WL; Rajasekaran T; Lim DWT; Tan A; Fong KW; Takano A; Cheng XM; Lim KH; Koh T; Ong BH; Tan EH; Toh CK; Skanderup AJ; Tan SH; Tan DSW
    JAMA Netw Open; 2021 Nov; 4(11):e2131892. PubMed ID: 34739062
    [TBL] [Abstract][Full Text] [Related]  

  • 32.
    Kok IC; Hooiveld JS; van de Donk PP; Giesen D; van der Veen EL; Lub-de Hooge MN; Brouwers AH; Hiltermann TJN; van der Wekken AJ; Hijmering-Kappelle LBM; Timens W; Elias SG; Hospers GAP; Groen HJM; Uyterlinde W; van der Hiel B; Haanen JB; de Groot DJA; Jalving M; de Vries EGE
    Ann Oncol; 2022 Jan; 33(1):80-88. PubMed ID: 34736925
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Phospho-EGFRTyr992 is synergistically repressed by co-inhibition of histone deacetylase (HDAC) and phosphatidylinositol 3-kinase (PI3K), which attenuates resistance to erlotinib in head and neck cancer cells.
    Chen X; Gao W; Yin G; Guo W; Huang J; Huang Z; Zhang Y
    Ann Transl Med; 2021 Sep; 9(18):1455. PubMed ID: 34734007
    [TBL] [Abstract][Full Text] [Related]  

  • 34. RAF and MEK Inhibitors in Non-Small Cell Lung Cancer.
    Adamopoulos C; Papavassiliou KA; Poulikakos PI; Papavassiliou AG
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731852
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeted therapies in non-small cell lung cancer: present and future.
    McLaughlin J; Berkman J; Nana-Sinkam P
    Fac Rev; 2023; 12():22. PubMed ID: 37675274
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pathways, resistance mechanisms and targeted interventions in non-small-cell lung cancer.
    Wang Z; Xing Y; Li B; Li X; Liu B; Wang Y
    Mol Biomed; 2022 Dec; 3(1):42. PubMed ID: 36508072
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cyclin-dependent kinase 4 upregulation mediates acquired resistance of dabrafenib plus trametinib in
    Hirai N; Hatanaka Y; Hatanaka KC; Uno Y; Chiba SI; Umekage Y; Minami Y; Okumura S; Ohsaki Y; Sasaki T
    Transl Lung Cancer Res; 2021 Sep; 10(9):3737-3744. PubMed ID: 34733624
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Molecular mechanisms of resistance to BRAF and MEK inhibitors in BRAF
    Facchinetti F; Lacroix L; Mezquita L; Scoazec JY; Loriot Y; Tselikas L; Gazzah A; Rouleau E; Adam J; Michiels S; Massard C; André F; Olaussen KA; Vassal G; Howarth K; Besse B; Soria JC; Friboulet L; Planchard D
    Eur J Cancer; 2020 Jun; 132():211-223. PubMed ID: 32388065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dabrafenib plus trametinib in patients with previously untreated BRAF
    Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
    Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promising Response to Dabrafenib Plus Trametinib in a Patient with Peritoneal Carcinomatosis from Non Small Lung Cancer Harboring
    Yagami Y; Nakahara Y; Manabe H; Yamamoto H; Otani S; Sato T; Igawa S; Kubota M; Sasaki J; Naoki K
    Onco Targets Ther; 2022; 15():1369-1374. PubMed ID: 36388158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.